NCT04536415View on ClinicalTrials.gov

Bioequivalence Study of Oseltamivir Phosphate and TAMIFLU Under Fed Condition in Healthy Volunteers

PHASE4CompletedINTERVENTIONAL

Enrollment

96

Participants

Timeline

Start Date

August 25, 2020

Primary Completion Date

August 27, 2020

Study Completion Date

August 27, 2020

Conditions

Bioequivalence

Interventions

DRUG

Oseltamivir Phosphate 75 mg capsules

Capsules, 75 mg, single, oral dose

DRUG

Tamiflu capsules 75 mg

Capsules, 75 mg, single, oral dose

Trial Locations (1)

08837

Austarpharma Llc, Edison

Sponsors

Lead Sponsor

Austarpharma, LLC

All Listed Sponsors

lead

Austarpharma, LLC

INDUSTRY

NCT04536415 - Bioequivalence Study of Oseltamivir Phosphate and TAMIFLU Under Fed Condition in Healthy Volunteers | Biotech Hunter | Biotech Hunter